CD8A and leukemia: Flow cytometry of peripheral blood 2 days after the first dose revealed that 1928z-carrying nanoparticles efficiently reprogrammed circulating T cells to recognize leukemia cells (mean 10% CAR+ among CD8+ ± 4.3%, Fig. 4d, e).